

DR. REDDY'S LABORATORIES LIMITED
PART I : STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2012

All amounts in Indian Rupees lakhs, except share data

Sl. No.	PARTICULARS	Quarter ended			Year ended	
		31.03.12	31.12.11	31.03.11	31.03.12	31.03.11
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Income from operations					
	a) Net sales / income from operations (Net of excise duty)	1,74,871	1,56,680	1,31,871	6,60,378	5,21,804
	b) License fees and service income	1,667	2,159	1,045	6,399	3,103
	c) Other operating income	2,292	1,930	1,750	7,193	5,534
	Total income from operations (net)	1,78,830	1,60,769	1,34,666	6,73,970	5,30,441
2	Expenses					
	a) Cost of materials consumed	52,603	42,708	34,220	1,79,201	1,39,676
	b) Purchase of stock-in-trade	8,530	7,236	9,272	30,763	33,104
	c) Changes in inventories of finished goods, work-in-progress and stock-in-	462	(5,582)	58	(10,476)	(7,899)
	d) Research and development expenses, net	16,744	14,947	16,153	58,129	51,286
	e) Employee benefits expense	23,596	20,666	18,897	86,614	70,113
	f) Selling expenses	14,502	19,585	11,171	62,506	47,713
	g) Provision for decline in the value of long-term investments, net	19,248	-	5,574	19,248	5,574
	h) Other expenditure	23,885	40,492	16,029	93,768	72,321
	i) Depreciation and amortisation	8,395	7,488	6,550	30,115	24,794
	Total expenses	1,67,965	1,47,540	1,17,924	5,49,868	4,36,682
3	Profit from operations before other income, finance costs and	10,865	13,229	16,742	1,24,102	93,759
4	Other income	26,288	2,417	2,911	8,178	11,960
5	Profit from ordinary activities before finance costs and exceptional items	37,153	15,646	19,653	1,32,280	1,05,719
6	Finance costs	1,567	1,693	425	6,362	538
7	Profit from ordinary activities after finance costs but before exceptional	35,586	13,953	19,228	1,25,918	1,05,181
8	Exceptional items	-	-	-	-	-
9	Profit from ordinary activities before tax (7 - 8)	35,586	13,953	19,228	1,25,918	1,05,181
10	Tax expense	14,407	3,150	2,641	34,682	15,850
11	Net Profit from ordinary activities after tax (9 - 10)	21,179	10,803	16,587	91,236	89,331
12	Extra-ordinary items	-	-	-	-	-
13	Net profit for the period / year (11 - 12)	21,179	10,803	16,587	91,236	89,331
14	Paid - up equity share capital (face value Rs.5/- each)	8,478	8,476	8,463	8,478	8,463
15	Paid up debt capital				1,52,811	1,43,880
16	Reserves (excluding revaluation reserve and debenture redemption reserve)				6,54,653	5,93,352
17	Debenture redemption reserve				8,664	185
18	Earnings per share for the period (in Rupees) per Rs.5/- share					
	a) Before Extra-ordinary items					
	- Basic	12.49	6.37	9.80	53.83	52.82
	- Diluted	12.43	6.34	9.75	53.56	52.51
	b) After Extra-ordinary items					
	- Basic	12.49	6.37	9.80	53.83	52.82
	- Diluted	12.43	6.34	9.75	53.56	52.51
		<i>(Not annualised)</i>	<i>(Not annualised)</i>	<i>(Not annualised)</i>		
19	a) Debt equity ratio				0.077	0.085
	b) Debt service coverage ratio				0.606	0.929
	c) Interest service coverage ratio				18.154	107.580

See accompanying notes to the financial results

DR. REDDY'S LABORATORIES LIMITED
PART II : SELECTED INFORMATION FOR THE QUARTER AND YEAR ENDED 31 MARCH 2012

A PARTICULARS OF SHAREHOLDING

	PARTICULARS	Quarter ended			Year ended	
		31.03.12	31.12.11	31.03.11	31.03.12	31.03.11
1	Public share holding*					
	- Number of shares (Face value Rs.5/- each)	9,76,27,569	9,65,43,537	9,41,24,752	9,76,27,569	9,41,24,752
	- Percentage of share holding	57.57	56.94	55.61	57.57	55.61
2	Promoters and promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of shares	-	-	21,00,000	-	21,00,000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	4.84	-	4.84
	- Percentage of shares (as a % of the total share capital of the company)	-	-	1.24	-	1.24
	b) Non-encumbered					
	- Number of shares	4,34,17,812	4,34,17,812	4,13,17,812	4,34,17,812	4,13,17,812
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	95.16	100.00	95.16
	- Percentage of shares (as a % of the total share capital of the company)	25.61	25.61	24.41	25.61	24.41

*Public Share Holding as defined under Clause 40A of Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt Holders)

B INVESTOR COMPLAINTS

Pending at the beginning of the quarter	1
Received during the quarter	4
Disposed of during the quarter	5
Remaining unresolved at the end of the quarter	Nil

Segment Information

All amounts in Indian Rupees lakhs, except share data

Sl. No.	PARTICULARS	Quarter ended			Year ended	
		31.03.12	31.12.11	31.03.11	31.03.12	31.03.11
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	Segment wise revenue, results and capital employed:					
	Segment revenue :					
	a) Pharmaceutical Services and Active Ingredients	79,855	63,092	56,592	2,59,069	2,05,467
	b) Global Generics	1,16,564	1,11,603	85,739	4,68,035	3,56,227
	c) Proprietary Products	59	44	50	189	252
	Total	1,96,478	1,74,739	1,42,381	7,27,293	5,61,946
	Less: Inter segment revenue	17,694	13,936	7,873	53,364	31,551
	Add : Other unallocable Income	26,334	2,383	3,069	8,219	12,006
	Total income	2,05,118	1,63,186	1,37,577	6,82,148	5,42,401
2	Segment results :					
	Profit / (loss) before tax and interest from each segment					
	a) Pharmaceutical Services and Active Ingredients	15,486	17,172	10,561	48,602	30,997
	b) Global Generics	24,679	33,579	15,764	1,57,976	96,210
	c) Proprietary Products	(4,489)	(5,301)	(3,875)	(16,800)	(11,693)
	Total	35,676	45,450	22,450	1,89,778	1,15,514
	Less: (i) Interest	1,567	1,693	425	6,362	538
	(ii) Other un-allocable expenditure, net	(1,477)	29,804	2,797	57,498	9,795
	Total profit before tax	35,586	13,953	19,228	1,25,918	1,05,181
3	Capital Employed :					
	a) Pharmaceutical Services and Active Ingredients	2,03,180	2,00,208	1,77,497	2,03,180	1,77,497
	b) Global Generics	2,72,931	2,85,365	2,65,407	2,72,931	2,65,407
	c) Proprietary Products	(1,754)	(3,386)	303	(1,754)	303
	d) Unallocated	1,97,438	1,90,191	1,58,793	1,97,438	1,58,793
	Total	6,71,795	6,72,378	6,02,000	6,71,795	6,02,000

DR. REDDY'S LABORATORIES LIMITED

Notes:

- 1 The audited results have been reviewed by the Audit Committee of the Board on 10 May 2012 and approved by the Board of Directors of the Company at their meeting held on 11 May
- 2 The results for the quarter and nine months ended 31 December 2011 have been subjected to a "Limited review" by the Statutory Auditors of the Company. An unqualified report has been

2 Statement of assets and liabilities

All amounts in Indian Rupees lakhs, except share data

Sl. No.	PARTICULARS	As at	As at
		31.03.12	31.03.11
		(Audited)	(Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders Funds		
	a) Share capital	8,478	8,463
	b) Reserves and surplus	6,63,317	5,93,537
	Sub-total - Shareholders' funds	6,71,795	6,02,000
2	Share Application money pending allotment	-	-
2	Non-current liabilities		
	a) Long-term borrowings	51,301	51,300
	b) Deferred tax liabilities (net)	2,003	10,076
	c) Other long-term liabilities	632	602
	d) Long-term provisions	2,120	1,966
	Sub-total - Non current liabilities	56,056	63,944
3	Current Liabilities		
	a) Short-term borrowings	1,02,036	93,110
	b) Trade payables	73,342	80,689
	c) Other current liabilities	98,437	58,895
	d) Short-term provisions	32,398	27,679
	Sub-total - Current liabilities	3,06,213	2,60,373
	TOTAL - EQUITY AND LIABILITIES	10,34,064	9,26,317
B	ASSETS		
1	Non-current Assets		
	a) Fixed Assets	2,51,439	2,23,688
	b) Non-current investments	2,27,049	2,46,181
	c) Long-term loans and advances	63,192	91,170
	Sub-total - Non-current assets	5,41,680	5,61,039
2	Current Assets		
	a) Current investments	20,702	-
	b) Inventories	1,32,662	1,06,317
	c) Trade receivables	1,94,345	1,77,051
	d) Cash and cash equivalents	84,904	6,624
	e) Short-term loans and advances	52,993	57,784
	f) Other current assets	6,778	17,502
	Sub-total - Current assets	4,92,384	3,65,278
	TOTAL - ASSETS	10,34,064	9,26,317

3 Ratios have been computed as follows:

- a) Debt Equity Ratio= Debt / Net Worth
[Debt: Long Term Borrowings (Current and Non current portions)]
[Net Worth: Share Capital + Reserves and Surplus]
- b) Debt Service Coverage Ratio = Earnings before interest and tax / (Interest expense during the period + Principal repayment for all the loan funds during the period)
- c) Interest Service Coverage Ratio = Earnings before interest and tax / Interest expense during the period
[Earnings before interest and tax: Profit from ordinary activities before tax + Interest expense]

4 During the year, there have been certain significant changes in the German generics market which are likely to cause an adverse impact on the price realization of some of the company's

5 The Board of Directors at their meeting held on 11 May 2012 have recommended a final dividend of Rs. 13.75 per share subject to approval of shareholders.

6 The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of the relevant

7 The figures of the earlier periods have been re-grouped to be in conformity with the new format prescribed under Clause 41 of the listing agreement.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place: Hyderabad
Date: 11 May 2012

Satish Reddy
Managing Director & Chief Operating Officer